NCT00930553
Who may be able to join
Who might be able to join this trial:
- You took part in a previous related study called CAMMS323 or CAMMS324, received the drug alemtuzumab, completed the full 2-year study, and did not go on to take other MS treatments afterward (except glatiramer acetate or interferon beta)
- You took part in CAMMS323 or CAMMS324, received the drug Rebif®, completed the full 2-year study, and did not go on to take other MS treatments afterward (except glatiramer acetate or another interferon beta medication)
- You took part in an earlier related study called CAMMS223
Who may not be able to join:
- You previously received alemtuzumab outside of the official Genzyme-sponsored studies mentioned above
- You are currently taking part in another research study (unless the trial organizers, Genzyme, have given special approval)
- You do not wish to receive the drug alemtuzumab as part of this trial
- You have a bleeding disorder or are taking blood-thinning medication
- You have been diagnosed with a blood-related autoimmune condition, such as idiopathic thrombocytopenia purpura
- You have a history of cancer (except a common, treatable form of skin cancer called basal cell carcinoma)
- You have had serious reactions to steroid treatments in the past, such as steroid-related psychiatric episodes
- You have a significant autoimmune disease other than MS
- You have a major psychiatric condition or epileptic seizures that are not well controlled with treatment
- You currently have an active infection or are considered at high risk of getting one
- You are able to have children and are unwilling to use a reliable form of contraception during treatment and for at least 6 months after each treatment cycle
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
11 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Annualized Relapse Rate (ARR); Annualized Relapse Rate (ARR) Before and After Receiving Alemtuzumab; Annualized Relapse Rate (ARR) Before and After Alemtuzumab Retreatment; Number of Participants With Sustained Accumulation of Disability (SAD); Number of Participants With Sustained Accumulation of Disability (SAD) Before and After Alemtuzumab Treatment: 2 Year Comparison
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.